Last reviewed · How we verify

intralesional vitamin D3

Combined Military Hospital Abbottabad · FDA-approved active Small molecule

Intralesional vitamin D3 activates vitamin D receptors in skin lesions to promote differentiation and apoptosis of abnormal keratinocytes and modulate local immune responses.

Intralesional vitamin D3 activates vitamin D receptors in skin lesions to promote differentiation and apoptosis of abnormal keratinocytes and modulate local immune responses. Used for Psoriasis (intralesional injection), Vitiligo (intralesional injection).

At a glance

Generic nameintralesional vitamin D3
SponsorCombined Military Hospital Abbottabad
Drug classVitamin D analog / immunomodulator
TargetVitamin D receptor (VDR)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Vitamin D3 (cholecalciferol) binds to the vitamin D receptor (VDR) in target tissues, triggering transcriptional changes that promote keratinocyte differentiation, reduce proliferation, and enhance local immunoregulation. When injected directly into lesions, it exerts anti-inflammatory and anti-proliferative effects on dermatological conditions. This local delivery approach concentrates the therapeutic effect at the disease site while minimizing systemic exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results